Total Funding
32
1
Total FundingDebt Financing raised
Growth Score
-2 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
868269
Edgemont Pharmaceuticals focuses on the field of neuroscience and develops novel drug formulations and therapies to improve patient care.
Douglas A. Saltel: Founder, Chairman & CEOPast Role: QRxPharma, President & COO
About the Company
Edgemont’s Management Team and Board of Directors have extensive experience and a proven track record of success in the pharmaceutical industry and the field of life sciences. Click on a link above or scroll down to learn more about the Edgemont leadership team.
